Skip to main content
Signal8
Launch Terminal

TRex Bio, Inc. (TRXB)

Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Medical - Pharmaceuticals

TRex Bio Inc. logo

TRex Bio Inc.

NASDAQ:TRXBHealthcare
-10.90%$13.81
AH Close$13.81+0.00%vs close
Mkt Cap$379.02M
Float10.24M
O/S27.45M
Inst Own-
Dilution
TRex Bio Inc. logoNASDAQ:TRXB$13.81-10.90%
FormDescription
13G
Beneficial Ownership Report
13D
Beneficial Ownership Report (Active)
2
13D
Beneficial Ownership Report (Active)
2
4
Statement of Changes in Beneficial Ownership
13G
Beneficial Ownership Report
4
Statement of Changes in Beneficial Ownership
8-K
5.03,9.01
2
4
Statement of Changes in Beneficial Ownership
S-8
SEC Filing
1
424B4
Prospectus
6
EFFECT
Notice of Effectiveness
3
Initial Statement of Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership

1-25 of 38